Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 84. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
A new standard of care for advanced-stage urothelial carcinoma1000
Tasadenoturev active in DIPG1000
From little subclones grow mighty oaks783
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes771
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC718
Ecological management of the microbiota in patients with cancer713
Novel ICI–TKI combination improves HCC outcomes709
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC609
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime606
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines576
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma551
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials507
Hodgkin lymphoma: great progress with room for improvement486
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety460
Current understanding and management of CAR T cell-associated toxicities427
Gut microbiota in colorectal cancer development and therapy422
Contrasting results with second-line CAR T cells in large B cell lymphoma416
Sacituzumab tirumotecan improves OS in mTNBC391
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials384
Ponatinib superior to imatinib in Ph+ ALL382
Mortality is similar with active monitoring378
From ESMO 2022376
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC365
Belzutifan as a new option in pheochromocytomas and paragangliomas338
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence288
Understanding and overcoming multidrug resistance in cancer285
Minimal residual disease as a target for liquid biopsy in patients with solid tumours283
Harnessing cytokines and chemokines for cancer therapy283
Humanized mouse models for immuno-oncology research279
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease277
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma277
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC275
Survival benefit with second-line combination in endometrial cancer272
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer270
Craniospinal irradiation improves leptomeningeal metastasis control269
Improving outcomes in patients with oesophageal cancer262
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours261
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests261
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs246
Biomarkers for immunotherapy of hepatocellular carcinoma239
Unresectable stage III non-small-cell lung cancer: state of the art and challenges239
Harnessing big data to characterize immune-related adverse events238
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response206
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship204
Spatial landscapes of cancers: insights and opportunities195
Approvals in 2022: overall survival, dose optimization, new approvals and beyond195
New CAPSTONE of SCLC therapy?193
SHINE a light: frontline ibrutinib for MCL191
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC185
Women with clinically node negative breast cancer can safely avoid axillary surgery172
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC171
From ESMO 2023: advances in lung cancer170
DREAMseq of therapy for BRAF-mutant melanoma155
Prospective comparisons support the use of navigational bronchoscopy155
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’144
Domvanalimab plus zimberelimab shows promise in upper-tract cancers143
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma141
Mitigating acute chemotherapy-associated adverse events in patients with cancer137
Targeting chromosomal instability in patients with cancer135
Circulating tumour DNA — looking beyond the blood134
Response to neoadjuvant endocrine therapy complements recurrence score125
Long-term outcomes following CAR T cell therapy: what we know so far125
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM121
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress120
Multiomics STEP up in correlative analysis of response to CAR T cells120
From the ESMO Congress 2023119
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas118
Sentinel lymph node biopsy improves surgical management of cervical cancer117
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC107
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL104
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma103
HAIC-FO improves outcomes in HCC101
Newly approved cancer drugs in China — innovation and clinical benefit100
Lung cancer in patients who have never smoked — an emerging disease99
Clinical implications of T cell exhaustion for cancer immunotherapy97
Claudin 18.2 as a novel therapeutic target97
Combining CAR T cells effective in RRMM95
Enhancing immunotherapy with tumour-responsive nanomaterials95
Targeted biopsy reduces detection of clinically insignificant cancer94
T-DXd effective as second-line therapy in G/GEJ cancers93
Second-line tarlatamab improves OS in SCLC90
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer89
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy86
Less-frequent surveillance is noninferior to annual mammography86
0.063683032989502